NCT05820672 A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
| NCT ID | NCT05820672 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ascendis Pharma Endocrinology Division A/S |
| Condition | Growth Hormone Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2023-03-20 |
| Primary Completion | 2033-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2023-03-20 with a primary completion date of 2033-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Eligibility Criteria
Inclusion Criteria: * Patients who are on treatment with SKYTROFA (lonapegsomatropin) * Patients being clinically managed in USA * Patients with an appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: * Patients participating in any interventional clinical study
Contact & Investigator
Medical Director, MD
STUDY DIRECTOR
Ascendis Pharma A/S
Frequently Asked Questions
Who can join the NCT05820672 clinical trial?
This trial is open to participants of all sexes, studying Growth Hormone Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05820672 currently recruiting?
Yes, NCT05820672 is actively recruiting participants. Contact the research team at Skybright_contact@ascendispharma.com for enrollment information.
Where is the NCT05820672 trial being conducted?
This trial is being conducted at Phoenix, United States, Orange, United States, Sacramento, United States, San Francisco, United States and 11 additional locations.
Who is sponsoring the NCT05820672 clinical trial?
NCT05820672 is sponsored by Ascendis Pharma Endocrinology Division A/S. The principal investigator is Medical Director, MD at Ascendis Pharma A/S. The trial plans to enroll 900 participants.